Clinical trial
Capecitabine in Treating Women With Advanced or Metastatic Breast Cancer
NCT00026442 · Pharmatech Oncology, Industry · Unknown status
Key facts
| NCT number | NCT00026442 |
|---|---|
| Title | Capecitabine in Treating Women With Advanced or Metastatic Breast Cancer |
| Official title | A Pilot Trial Of Two Different Doses Of Capecitabine (XELODA) In Patients With Advanced And/Or Metastatic Breast Cancer |
| Lead sponsor | Pharmatech Oncology, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | capecitabine |
| Start date | Nov 1, 2001 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 18, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: